The trial assessed tislelizumab plus chemotherapy in gastric cancer patients. Credit: CoRus13 / commons.wikimedia.org.

BeiGene has reported that its Phase lll RATIONALE 305 trial of tislelizumab plus chemotherapy against chemotherapy alone, to treat patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, irrespective of PD-L1 status, met its primary endpoint.

The international trial met its endpoint of overall survival (OS), with no new safety signals observed for tislelizumab.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Progression-free survival, overall response rate, duration of response and safety are included as the secondary endpoints.

The randomised, double-blind, placebo-controlled trial enrolled 997 patients from 13 countries and regions worldwide.

During the trial, the patients were randomised into a 1:1 ratio to receive either tislelizumab or a placebo combined with chemotherapy.

Tislelizumab, a humanised IgG4 anti-PD-1 monoclonal antibody, is currently under evaluation by the US Food and Drug Administration and the European Medicines Agency (EMA) for the treatment of advanced or metastatic oesophagal squamous cell carcinoma following previous chemotherapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The EMA is also reviewing the antibody for advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy along with chemotherapy for advanced or metastatic NSCLC formerly untreated.

Tislelizumab has already received approval for use in ten indications in China.

Earlier, BeiGene reported better OS for the therapy combination than chemotherapy in the PD-L1 high group at an interim analysis.

In the final analysis, tislelizumab plus chemotherapy showed superior OS compared with chemotherapy in the intent-to-treat (ITT) group.

BeiGene Solid Tumors chief medical officer Mark Lanasa said: “Gastric cancer is the fifth most common cancer globally, and the prognosis for patients with advanced or metastatic conditions remains inadequate; these data support tislelizumab combined with chemotherapy as a potential first-line treatment option for patients with locally advanced, unresectable or metastatic gastric or gastroesophageal junction cancer.”